Synaptic Systems - Oligo-Abeta-pE3

Cat. No.: 218 511

Amount: 100 µg

Price: $415.00

Cat. No. 218 511	100 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H₂O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications	WB: 1 : 500 (see remarks) gallery IP: not tested yet ICC: not tested yet IHC: 1 : 100 gallery IHC-P: 1 : 100 (see remarks) gallery ELISA: yes (see remarks) Western blot (WB); separation of proteins by PAGE and subsequent transfer to a membrane. Detection of target molecules is carried out with antibodies. Some antibodies require special sample preparation steps. For details, please refer to the “Remarks” section. Immunoprecipitation (IP); Immunoisolation or pulldown of a target molecule using an antibody. For details and product specific hints, please refer to the ”Remarks” section. Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section. Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section. Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Enzyme-linked immunosorbent assay (ELISA); a frequently employed method to quantify target-molecules in solution. The detection of some proteins requires special solubilization steps. For further information, please refer to the „Remarks“ section.
Important note for users	The mouse monoclonal antibody clone 9D5, Cat. No. 218 511, is patented (patent application PCT/EP2011/002739). By purchasing this antibody the customer acquires rights to use this product for research purposes only. Any diagnostic and therapeutic in vitro or in vivo use is explicitly excluded.
Clone	9D5
Subtype	IgG2b (κ light chain)
Immunogen	Synthetic peptide corresponding to AA 3 to 38 from human Oligo-Abeta-pE3 (UniProt Id: P05067)
Reactivity	Reacts with: human (P05067), mouse (P12023). Other species not tested yet.
Specificity	Recognizes specific oligomeric structures formed preferentially by Abeta-pE3.
Remarks	WB: We recommend the Invitrogen NativePAGE system in combination with PVDF blotting membranes. Boil membrane after blotting for 3min. Peptide preparation: Synthetic Abeta peptides were monomerized in 70 % formic acid, and the solvent was evaporated in a speed-vac immediately. Prior to each experiment, peptides were dissolved in 0.3 % ammonia, underwent ultrasonic treatment, and were further diluted to an end concentration of 0.15 % ammonia. IHC-P: Antigen retrieval with formic acid is required. ELISA: Suitable as capture antibody for sandwich-ELISA with cat. no. 218 011BT as detector antibody.
Data sheet	218_511.pdf

References for Oligo-Abeta-pE3 - 218 511

Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis.
Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, et al.
The Journal of biological chemistry (2010) 28553: 41517-24. 218 511 WB, IHC, ELISA

I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
Sieczkowski E, Milenkovic I, Venkataramani V, Giera R, Ströbel T, Höftberger R, Liberski PP, Auff E, Wirths O, Bayer TA, Kovacs GG, et al.
Journal of Alzheimer's disease : JAD (2015) 441: 103-14. 218 511 IHC; tested species: human

Oxidative Stress during the Progression of β-Amyloid Pathology in the Neocortex of the Tg2576 Mouse Model of Alzheimer's Disease.
Porcellotti S, Fanelli F, Fracassi A, Sepe S, Cecconi F, Bernardi C, Cimini A, Cerù MP, Moreno S
Oxidative medicine and cellular longevity (2015) 2015: 967203. 218 511 IHC

Oligomeric pyroglutamate amyloid-β is present in microglia and a subfraction of vessels in patients with Alzheimer's disease: implications for immunotherapy.
Wirths O, Hillmann A, Pradier L, Härtig W, Bayer TA
Journal of Alzheimer's disease : JAD (2013) 354: 741-9. 218 511 IHC

Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates.
Venkataramani V, Wirths O, Budka H, Härtig W, Kovacs GG, Bayer TA
Journal of Alzheimer's disease : JAD (2012) 292: 361-71. 218 511 IHC

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease.
Bayer TA, Wirths O
Acta neuropathologica (2014) 1276: 787-801. 218 511 IHC-P; tested species: human

Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?
Bayer TA, Wirths O
Biochemical Society transactions (2011) 394: 857-61. 218 511

Cat. No.: 218 511

Amount: 100 µg

Price: $415.00

Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?
Bayer TA, Wirths O
Biochemical Society transactions (2011) 394: 857-61. 218 511

IHC

IHC-P

Background

Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the amyloid beta-peptides (Abeta, Aβ) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and pyroglutamyl (pGlu)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotxic variants of Abeta; Abeta-pE3 and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.

1 ) Sullivan CP et al., Neurosci. Lett. (2011)
2 ) Perez-Garmendia R et al., J. Neuroimmunol. (2010)
3 ) Schilling S et al., Nat. Med. (2008)
4 ) Hook V et al., Biol. Chem. (2008)
5 ) Böhme L et al., Biol. Chem. (2008)
6 ) Schilling S et al., J. Neurochem. (2008)
7 ) Wiltfang J et al., J. Biol. Chem. (2001)
8 ) Wood SJ et al., J. Mol. Biol. (1996)
9 ) Kuo YM et al., J. Biol. Chem. (1996)

Protocols

IHC

IHC-P

ELISA

Standard protocol

Oligo-Abeta-pE3 antibody - 218 511

References for Oligo-Abeta-pE3 - 218 511